Bolt Biotherapeutics (NASDAQ:BOLT) Cut to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of Bolt Biotherapeutics (NASDAQ:BOLTGet Rating) from a buy rating to a hold rating in a research report report published on Friday, reports.

According to Zacks, “Bolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company’s principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California. “

Separately, Morgan Stanley lowered shares of Bolt Biotherapeutics from an overweight rating to an equal weight rating in a research report on Thursday, January 6th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of Buy and a consensus price target of $28.81.

Shares of NASDAQ:BOLT opened at $1.56 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 8.87 and a current ratio of 8.87. The firm has a fifty day moving average price of $2.74 and a 200 day moving average price of $5.45. Bolt Biotherapeutics has a fifty-two week low of $1.55 and a fifty-two week high of $25.44.

Bolt Biotherapeutics (NASDAQ:BOLTGet Rating) last released its quarterly earnings data on Wednesday, March 30th. The company reported ($0.73) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.08. Research analysts expect that Bolt Biotherapeutics will post -2.97 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in BOLT. Morgan Stanley purchased a new stake in shares of Bolt Biotherapeutics in the first quarter valued at $156,000. Millennium Management LLC purchased a new stake in shares of Bolt Biotherapeutics in the second quarter valued at $494,000. SG Americas Securities LLC purchased a new stake in shares of Bolt Biotherapeutics in the third quarter valued at $178,000. Dupont Capital Management Corp purchased a new stake in shares of Bolt Biotherapeutics in the third quarter valued at $338,000. Finally, Deutsche Bank AG raised its stake in shares of Bolt Biotherapeutics by 181.1% in the third quarter. Deutsche Bank AG now owns 19,362 shares of the company’s stock valued at $244,000 after acquiring an additional 12,475 shares during the period. 97.85% of the stock is currently owned by institutional investors and hedge funds.

Bolt Biotherapeutics Company Profile (Get Rating)

Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages.

Read More

Get a free copy of the Zacks research report on Bolt Biotherapeutics (BOLT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with's FREE daily email newsletter.